惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

L
LangChain Blog
Recent Announcements
Recent Announcements
GbyAI
GbyAI
H
Hackread – Cybersecurity News, Data Breaches, AI and More
Microsoft Azure Blog
Microsoft Azure Blog
N
Netflix TechBlog - Medium
人人都是产品经理
人人都是产品经理
MongoDB | Blog
MongoDB | Blog
D
DataBreaches.Net
freeCodeCamp Programming Tutorials: Python, JavaScript, Git & More
WordPress大学
WordPress大学
U
Unit 42
腾讯CDC
D
Docker
The GitHub Blog
The GitHub Blog
阮一峰的网络日志
阮一峰的网络日志
Vercel News
Vercel News
I
InfoQ
Jina AI
Jina AI
爱范儿
爱范儿
宝玉的分享
宝玉的分享
博客园 - Franky
G
Google Developers Blog
P
Proofpoint News Feed

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call...
SA Transcripts · 2026-05-08 · via All Articles on Seeking Alpha

Q1: 2026-05-07 Earnings Summary

EPS of -$0.37 misses by $0.03

 | 

Revenue of

$0.00

beats by $0.00

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call May 7, 2026 8:00 AM EDT

Company Participants

Lindsey Allen - Head of Investor Relations & Communications
Justin Klee - Co-CEO & Director
Dan Monahan - Chief Commercial Officer
Camille Bedrosian - Chief Medical Officer
James Frates - Chief Financial Officer
Joshua Cohen - Co-Founder, Co-CEO & Director

Conference Call Participants

Seamus Fernandez - Guggenheim Securities, LLC, Research Division
Jacob Ormes
Kevin Strang - Goldman Sachs Group, Inc., Research Division
Michael DiFiore - Evercore ISI Institutional Equities, Research Division
Marc Goodman - Leerink Partners LLC, Research Division
Geoffrey Meacham - Citigroup Inc., Research Division
Rami Katkhuda - LifeSci Capital, LLC, Research Division
Mark Hitrik - Stifel, Nicolaus & Company, Incorporated, Research Division
Samuel Lee - Mizuho Securities USA LLC, Research Division
Christopher Chen - Robert W. Baird & Co. Incorporated, Research Division
Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division

Presentation

Operator

Good morning. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals First Quarter 2026 Earnings Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to Lindsey Allen, Vice President, Investor Relations and Communications. Please proceed.

Lindsey Allen
Head of Investor Relations & Communications

Good morning, and thank you all for joining us today to discuss our first quarter 2026 financial results and business update. With me on the call today are Josh Cohen and Justin Klee, our Co-CEOs; Dr. Camille Bedrosian, our Chief Medical Officer; Jim Frates, our Chief Financial Officer; and Dan Monahan, our Chief Commercial Officer.

Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are based